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Summary
 
Cells from the bone marrow can present peptides that are derived from tumors, transplants, and
self-tissues. Here we describe how dendritic cells (DCs) process phagocytosed cell fragments
onto major histocompatibility complex (MHC) class II products with unusual efficacy. This
was monitored with the Y-Ae monoclonal antibody that is specific for complexes of I-A
 
b
 
MHC class II presenting a peptide derived from I-E
 
a
 
. When immature DCs from I-A
 
b
 
 mice
were cultured for 5–20 h with activated I-E
 
1
 
 B blasts, either necrotic or apoptotic, the DCs
produced the epitope recognized by the Y-Ae monoclonal antibody and stimulated T cells re-
active with the same MHC–peptide complex. Antigen transfer was also observed with human
cells, where human histocompatibility leukocyte antigen (HLA)-DR
 
a
 
 includes the same pep-
tide sequence as mouse I-E
 
a
 
. Antigen transfer was preceded by uptake of B cell fragments into
MHC class II–rich compartments. Quantitation of the amount of I-E protein in the B cell frag-
ments revealed that phagocytosed I-E was 1–10 thousand times more efficient in generating
MHC–peptide complexes than preprocessed I-E peptide. When we injected different I-E–
bearing cells into C57BL/6 mice to look for a similar phenomenon in vivo, we found that
short-lived migrating DCs could be processed by most of the recipient DCs in the lymph node.
The consequence of antigen transfer from migratory DCs to lymph node DCs is not yet
known, but we suggest that in the steady state, i.e., in the absence of stimuli for DC matura-
tion, this transfer leads to peripheral tolerance of the T cell repertoire to self.
Key words: apoptosis • necrosis • dendritic cells • major histocompatibility complex–peptide 
complexes • immature dendritic cells
 
D
 
uring the maintenance of tolerance (1–3) and the re-
jection of malignant cells (4) and transplants (5–12),
there is a transfer of antigens from tissues to the MHC class
I and II products of APCs. Mechanisms underlying this
“cross-presentation” phenomenon need to be elucidated,
and a priori may simply involve the release of peptides
from donor cells (e.g., tumor, transplant, self-tissue) to re-
cipient APCs. Recent tissue culture studies have used T
cell readouts to demonstrate that dendritic cells (DCs)
 
1
 
 can
present antigen to influenza-specific CTLs after transfer of
a dominant matrix peptide from apoptotic cells (13, 14).
Here we directly monitor the formation of specific MHC
class II–peptide complexes in vitro and in vivo after the
phagocytosis of cell fragments. We find that DCs, known
for strong costimulatory functions, are also unusually effi-
cient at forming MHC–peptide complexes from phagocy-
tosed cells, some 1–10 thousand times more efficiently
than an exposure to preprocessed peptide. A comparable
phenomenon is observed in vivo when short-lived migra-
tory DCs migrate via afferent lymphatics to the T cell areas
of the lymph node. Antigen is transferred from the injected
 
1
 
Abbreviations used in this paper:
 
 DC, dendritic cell; MIIC, MHC class II
compartment.
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DCs to the recipient DCs in the lymph node, a phenome-
non that may underlie cross-priming after transplantation,
and cross-tolerance to self-tissues in the steady state.
 
Materials and Methods
 
Mice.
 
Adult 6–8-wk-old mice (BALB/c, C57BL/6, C57BL/6 
 
3
 
DBA/2 F1) of both sexes were from Taconic Farms Inc.
(Germantown, NY) and Japan SLC (Hamamatsu, Japan), and
B10.A(4R) from The Jackson Laboratory (Bar Harbor, ME).
B6.I-E transgenic mice, line 107 (15), were provided by Dr. R.
Flavell (Yale University, New Haven, CT).
 
Cells.
 
DCs were generated from bone marrow progenitors
by culture in rGM-CSF as described (16). The cultures were set
up in 24-well plates (Costar Corp., Cambridge, MA) and used at
day 6 when the wells were covered with aggregates of immature
DCs. By days 7–8, aggregates release 
 
z
 
10
 
5
 
 mature DCs/well
(16). Immature but not mature DCs are phagocytic (17). B blasts
were induced for 3–4 d with LPS (
 
Escherichia coli
 
 0111:B4, 25 
 
m
 
g/
ml; Sigma Chemical Co, St. Louis, MO), or for 2 d with anti-
 
m
 
(5 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgM; Jackson ImmunoResearch
Labs, West Grove, PA) and IL-4 (5 ng/ml; GIBCO BRL, Gaith-
ersburg, MD). Both types of B blasts gave similar results in tests
for antigen transfer. Small B cells were spleen cells passed over
Sephadex G10 columns and depleted of T cells with antibodies
(Thy-1, TIB 99; CD4, L3T4; and CD8, TIB 211; all from Amer-
ican Type Culture Collection, Rockville, MD) and complement.
Human cells were plastic adherent monocytes from PBMCs and
EBV-transformed B cell lines. Necrosis was induced either by
freeze–thawing three to four times, or in the case of mouse B
cells, with monoclonal J11d and rabbit complement in MEM.
Apoptosis was induced by exposure to UV light. The surface of
most cells became annexin V–positive after 8–10 h.
 
Antibodies.
 
The Y-Ae hybridoma was provided by Dr. C. Jane-
way, Jr. (Yale University, New Haven, CT) and grown serum-free.
The IgG2b antibody was purified on protein A–Sepharose, biotiny-
lated, and used in the FACS
 
Ò
 
 along with PE-streptavidin to detect
MHC class II–peptide complexes (18). A mouse IgG2b anti–human
TCR antibody was the nonreactive control (PharMingen, San
Diego, CA). The cells were double labeled for FACS
 
Ò
 
 and for mi-
croscopy with FITC antibodies to CD8, CD11c, CD86, I-A
 
b
 
 (AF6-
120.1), I-A
 
d
 
 (39-10-8), and I-E (14-4-4S; all from PharMingen).
 
Capture of Cell-derived Peptides In Vitro.
 
Bone marrow DCs
were generated in 24-well plates for 6 d in GM-CSF, gently
washed to remove mature floating DCs, and then fed B blasts,
human cells, or peptide (residues 56–73 of I-E
 
a
 
). Alternatively,
the 6-d DCs were added to the B blasts. During uptake, the DCs
matured with high levels of surface CD86.
 
Confocal Microscopy.
 
Cells were resuspended in serum-free
RPMI 1640, attached to Alcian Blue–coated glass coverslips for
20–30 min at 37
 
8
 
C, fixed in 4% paraformaldehyde for 20 min at
room temperature, washed three times in PBS, and permeabilized
for 15 min in PS (0.05% saponin, 10 mM Hepes, pH 7.4, 10 mM
glycine, pH 8, 10% goat serum, RPMI 1640). All incubations and
washes were then in PS. Cells were incubated in primary anti-
body (see figure legends) for 30 min at room temperature,
washed four times in PBS, followed by secondary FITC- or
Texas Red–conjugated antibody for 30 min at room temperature,
washed four times in PS, once in PBS, once in water, and
mounted in Mowiol (Calbiochem Corp., La Jolla, CA) on glass
slides for analysis by immunofluorescence and confocal micros-
copy (0.5–1.0-
 
m 
 
optical sections). The observed double labeling
of phagocytic vacuoles for donor B cell antigens and recipient
DC MHC II was verified by an examination of perpendicular
sections through the phagosomes.
 
Antigen-presentation Assays.
 
The 20.6 T–T hybridoma recog-
nizes the MHC II–peptide complex that is detected with Y-Ae
mAb (19). Graded doses of APCs, which had been fixed in 1.0%
HCHO for 10 min at room temperature, were added to 2 
 
3 
 
10
 
4
 
hybridoma cells in flat-bottomed microtest plates. At 24 h, IL-2
in the supernatants was detected using a growth assay for Con
A–stimulated T blasts.
 
Quantitation of I-E Molecules in B Cells.
 
Mature I-E hetero-
dimers were quantified in a binding assay with 
 
125
 
I-labeled 14-
4-4S mAb (PharMingen). The B blasts were fixed in 4% PFA and in
some cases, 0.05% saponin, to include intracellular pools. To ver-
ify that the bulk of the I-E in 4-d B blasts was recognized by 14-
4-4S, whole cell lysates were lysed in 50 mM Tris, pH 7.4, 100
mM NaCl, 0.5% Triton X-100, and protease inhibitors. Lysates
were precleared with preimmune rabbit sera and zysorbin
(Zymed Laboratories, Inc., So. San Francisco, CA). Protein
A–Sepharose CL-4B (Amersham Pharmacia Biotech, Inc., Piscat-
away, NY) was incubated with rabbit anti–mouse IgG2a bridging
antibody and then with 14-4-4S (or control Ig). Total and immu-
noadsorbed lysates were run on 10% SDS-PAGE, transferred to
nitrocellulose, and blotted for total I-E
 
a
 
 using a rabbit antiserum
specific for the cytoplasmic tail of I-E
 
a
 
 (provided by Dr. R. Ger-
main, National Institutes of Health, Bethesda, MD).
 
Capture of Cell-derived Peptides In Vivo.
 
2 
 
3 
 
10
 
6
 
 I-E
 
1
 
 DCs
from BALB/c or B6.I-E transgenic mice were injected in PBS
into the footpads of C57BL/6 (H-2
 
b
 
) mice. At 2 d, the popliteal
lymph nodes were frozen in OCT embedding medium, sec-
tioned, fixed in absolute acetone for 10 min, and stained succes-
sively with biotin–Y-Ae (or anti–human TCR IgG2b as control),
avidin–alkaline phosphatase conjugates, rat antibody to B220 to
label B cell follicles, and peroxidase-labeled mouse anti–rat Ig.
We thereby located blue Y-Ae
 
1
 
 cells relative to B cells in brown.
Negative controls were mice that lacked I-E on the donor B
blasts (B10.A[4R] or C57BL/6) or I-A
 
b
 
 in the recipients (CBA/J,
H-2
 
k
 
). To identify Y-Ae
 
1
 
 cells in the FACS
 
Ò
 
, DCs were en-
riched from the nodes (20) and double labeled with biotin Y-Ae
(or nonreactive IgG2b mAb as control), PE-streptavidin, and dif-
ferent FITC conjugates to CD8, B220, CD11c, I-A
 
b
 
, and I-A
 
d
 
.
 
Results
 
Transfer of Antigen from B Blasts to the MHC Class II Prod-
ucts of DCs.
 
To demonstrate that DCs could present pep-
tides from other cells, we cultured C57BL/6 DCs (I-E
 
a
 
2
 
,
I-A
 
b
 
1
 
) with activated BALB/c B blasts (I-E
 
a
 
1
 
, I-A
 
b
 
2
 
) and
monitored reactivity with Y-Ae mAb. Y-Ae is specific for
an MHC class II–peptide complex formed when I-A
 
b
 
 pre-
sents the I-E
 
a 
 
56–73 peptide (18). The DCs were from 6-d
GM-CSF–stimulated marrow cultures, known to have
phagocytic activity, whereas mature nonphagocytic DCs
predominate at days 7–8 (17). When H-2
 
b
 
 DCs were ex-
posed for 20 h to 1 
 
m
 
M I-E
 
a
 
 peptide, the specific MHC–
peptide detected by Y-Ae developed (Fig. 1 
 
A
 
). Y-Ae sig-
nal also developed when I-E
 
1
 
 B blasts, but not I-E
 
2
 
 B
blasts, were added at a ratio of 2–10 blasts per DC (Fig. 1
 
A
 
). The Y-Ae
 
1
 
 cells had mature DC markers (CD86
 
high
 
,
CD11c
 
1
 
, I-A
 
b
 
1
 
, I-Ad
 
2
 
; Fig. 1 
 
B
 
). No Y-Ae was detected
when B blasts were added to H-2
 
d
 
 DCs, and 4-d blasts gave 
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much stronger Y-Ae signals than unstimulated B cells (not
shown).
Xenograft immunity also involves presentation of xeno-
geneic peptides by recipient MHC II products (11). Hu-
man HLA-DR
 
a
 
 has the identical sequence to mouse I-E
 
a
 
56–73 (21, 22). A Y-Ae signal developed when mouse
DCs were cultured with either apoptotic or necrotic hu-
man B lymphoblastoid cell lines (Fig. 1 
 
C
 
) or monocytes
(not shown).
The functionality of the Y-Ae epitope was tested using a
hybridoma that responds to a similar I-A
 
b
 
/I-E
 
a
 
 peptide
complex (19). After a 20-h exposure to either I-E
 
a
 
 peptide
or B blasts, the DCs were almost as potent APCs as DCs
expressing endogenous I-A
 
b
 
 complexes (I-A
 
b
 
 
 
3 
 
I-E
 
1
 
 F1
mice), as indicated by IL-2 production (Fig. 1 
 
D
 
).
 
Antigen Processing Is Required for Transfer of Peptide from B
Blasts to DCs.
 
To approach mechanisms, we first ruled out
release of peptide from B blasts to DCs. Y-Ae labeling did
not develop if the cells were separated by Transwell filters, or
if B blasts were added to mature DCs that express high sur-
face MHC II but are nonphagocytic (Fig. 2 
 
A
 
). Both apop-
totic (induced by exposing the B blasts to UV light 10 h be-
fore addition to the DCs; not shown) and necrotic B blasts
(induced by freeze–thawing in Fig. 1 
 
C
 
, and by antibody and
complement–mediated lysis in Fig. 2 
 
A
 
) were processed by
DCs. A fraction (20–40%) of mouse B cells and human EBV
lines die during overnight culture, and we could not demon-
strate an increase in antigen transfer if these cells were in-
duced to apoptose or necrose before coculture with imma-
ture DCs (compare 
 
B blast 
 
with 
 
Ab/C
 
 in Fig. 2 
 
A
 
).
Figure 1. Development of MHC–pep-
tide complexes consisting of a B cell–
derived I-Ea peptide and DC-derived, I-Ab
MHC II products. (A) C57BL/6 I-Ab DCs
were cultured for 20 h with no peptide, 10
mM peptide, or 2 3 106 B blasts from H-2d
BALB/c (I-E1) or H-2b C57BL/6 (I-E2)
mice. CD86-rich DCs (arrows) acquired I-E
peptide (Y-Ae stain) from I-E1 B blasts. No
labeling was seen with an IgG2b isotype
control to Y-Ae (right). (B) As in A, but
DC–BALB/c B blast cocultures (or DCs
alone, right) were labeled with other mAbs
to show that CD11c1, I-Ab1, I-Ad2 DCs
selectively acquired Y-Ae (arrows). (C)
EBV-transformed human B cell lines (3
cells/DC; necrotic and apoptotic) served as
a source of I-Ea peptide for mouse DCs.
An isotype-matched IgG2b antibody was
used as a control for the specific Y-Ae label-
ing that developed on the CD86-rich DCs.
(D) As in A, but the DCs were sorted as
CD11c/CD861 cells from the 20-h cul-
tures, fixed in 1% formaldehyde for 10 min
to block further processing, and added in
graded doses to a T–T hybridoma that is
specific for the same epitope as the Y-Ae
mAb. At 24 h, medium was tested in an IL-2
bioassay ([3H]TdR uptake).2166 Dendritic Cells Efficiently Process Cellular Fragments
Since the findings suggested that peptides had to be pro-
cessed by immature phagocytic DCs (17), we tested if
NH4Cl, which inhibits acidification and proteolysis within
endocytic vacuoles, could block the formation of the Y-Ae
epitope. This was indeed the case, with a complete block
being observed at 10 mM (Fig. 2 B). The NH4Cl block
was reversible.
We then used confocal microscopy to look directly for
the internalization of B blasts by DCs. We rarely observed
profiles of intact B cells in DCs, but after 6 h of coculture,
most DCs contained B cell fragments (I-Ad, I-Ed, and
B2201) in vacuoles that had markers of MHC II–rich com-
partments or MHC II compartments (MIICs) (MHC II,
LAMP1, and H-2M1; Fig. 2 C, arrows).
Phagocytosis of B Blasts Precedes Formation of MHC II–Pep-
tide Complexes by DCs. To demonstrate that phagocyto-
sis preceded the formation of the Y-Ae epitope, B blasts
were fed to DCs in 20 mM NH4Cl. After 20 h, DCs were
FACSÒ separated from residual B blasts and recultured for
12 h without NH4Cl. NH4Cl completely blocked Y-Ae
epitope development (Fig. 3 A, top), even within saponin-
permeabilized cells (not shown), but the Y-Ae reappeared
after removal of NH4Cl (Fig. 3 A, bottom). The block im-
posed by NH4Cl seemed primarily at the level of I-E pro-
cessing, rather than peptide loading, since addition of I-Ea
peptide for 20 h to NH4Cl cultures led to strong Y-Ae sig-
nals comparable to nonblocked cultures (Fig. 3 B).
When DCs were sorted from 20-h B blast–DC cocul-
tures and examined by confocal microscopy, DCs no
longer had B cell fragments (vs. 6 h in Fig. 2 C), unless
NH4Cl-treated (Fig. 3 C, middle). When NH4Cl-treated B
blast–containing DCs were chased for 12 h without NH4Cl,
the phagocytosed B cells were degraded and high levels of
surface MHC II accumulated (Fig. 3 C, right).
The Unusual Efficiency of Processing of Phagocytosed B
Cells. In kinetic studies comparing Y-Ae expression de-
rived from preprocessed I-Ea peptide with B blasts, we
found that MHC–peptide complexes appeared after 5 h of
Figure 2. Antigen transfer re-
quires cellular processing. (A) B
blasts were separated from im-
mature DCs (6-d bone marrow
cultures) by a Transwell filter
(0.45-m pores), or added to ma-
ture DCs (nonadherent cells
from day 8 marrow cultures; see
Materials and Methods). Al-
though Y-Ae signals developed
on immature day 6 marrow DCs
upon exposure to B blasts, in-
cluding B blasts killed with anti-
body and complement (Ab/C9),
no Y-Ae developed if the DCs
were separated by a filter or if
mature nonphagocytic DCs were
used. (B) Graded doses of
NH4Cl were added to cocultures
of I-E1 B blasts and I-Ab DCs,
and Y-Ae epitope formation was
measured 20 h later. The block
was fully reversible within 12 h
(see Fig. 3). (C) I-Ad/I-E1 B
blasts were cultured for 6 h with
I-Ab1/I-E2 bone marrow–
derived DCs. B cell fragments
(red) were visualized by confocal
microscopy using mAbs to B cell
markers I-Ad (mAb 39-10-8),
I-E (mAb 14-4-4S), and B220
(mAb RA3-3A1/6.1; middle,
B220 stain is shown). Immature
DCs (left) were identified using
antibody specific for I-Ab (biotin
AF6-120.2). Merging of the
two images (right) showed that
the B cell fragments had been in-
ternalized into MHC II1 struc-
tures (arrows) in immature DCs.
Most DCs only had one to two
B cell fragments, but this micro-
graph was selected to emphasize
the location of most B cell frag-
ments in MIICs.2167 Inaba et al.
culture, reached a plateau at 15–25 h, and remained stable
for 3 d; 1 mM peptide gave comparable Y-Ae signals to 106
B blasts (Fig. 4 A).
We then measured the level of I-E in the B blasts. Fixed
and fixed–permeabilized blasts had 1.5–2.0 3 105 mature
I-E molecules/cell, using 125I-labeled 14-4-4S antibody (23),
corresponding to 0.3 nM I-E protein in a 1-ml culture. 14-
4-4S recognizes mature MHC II heterodimers (24) and not
Figure 3. Antigen transfer is
preceded by phagocytosis. (A)
Top, the formation of Y-Ae after
20 h of DC–B blast coculture
with or without 20 mM NH4Cl.
The DCs then were sorted as
double positive for PE-CD11c
and FITC-CD86, or in a second
experiment, just FITC-CD861,
and cultured for 12 h without
NH4Cl (bottom). Y-Ae (biotin
Y-Ae followed by Cychrome-
Avidin) quickly regenerated in
DCs that had been blocked by
NH4Cl. No Y-Ae was found in
saponin-permeabilized samples
of NH4Cl-treated cultures. (B)
Immature DCs were cultured
with or without 20 mM NH4Cl
and 10 mM preprocessed I-E
peptide for 15 h, and then Y-Ae
levels were measured on the
FACSÒ. CD86 (not shown) and
Y-Ae epitope formed in the
presence of NH4Cl. (C) DCs
prepared exactly as in A were
examined by confocal micros-
copy. DC MHC II (I-Ab, green)
was visualized relative to B cell
MHC II (I-E, red). When imma-
ture DCs were allowed to inter-
nalize B blasts for 20 h in the ab-
sence of NH4Cl, B cell fragments
were largely degraded (although
fragments were detected after
just 6 h; see Fig. 2 C), and the
DCs acquired a mature pheno-
type with characteristic den-
drites and high MHC II on the
plasma membrane (left). How-
ever, if B blasts were internalized
in the presence of 20 mM
NH4Cl, abundant I-E1 frag-
ments were found within DCs in
MHC II1 phagolysosomes, and
the MHC II was arrested intra-
cellularly (middle). Upon removal
of the NH4Cl and culture for an
additional 12 h, the DCs ma-
tured and the internalized B cell
fragments largely disappeared,
presumably due to degradation
(right).2168 Dendritic Cells Efficiently Process Cellular Fragments
Figure 4. Efficiency of antigen transfer after phagocytosis. (A) As in
Fig. 1 A, C57BL/6 DCs were cultured for the indicated times with doses
of I-Ea peptide, or 106 B blasts from BALB/c mice, and double labeled
for Y-Ae and CD86. Y-Ae signals (Mean Fluorescence Index) are shown for
CD861 mature DCs. (B) Assays for the stability of the I-E peptide during
culture. Graded doses of I-E peptide were added to day 6 marrow DCs,
and the levels of Y-Ae (Mean Fluorescence Intensity) were measured 20 h
later (circles). At this time, supernatants were harvested from the cultures
(diamonds) in parallel with peptide that was cultured in the absence of cells
for 20 h (triangles). Both sources of peptide were then added to fresh cul-
tures of immature marrow DCs, and Y-Ae epitope formation was com-
pared 20 h later. (C) Distribution of MHC II in fresh B cells (left) and 4-d
splenic B blasts (right). The latter are processed best by DCs and express
z1.5 3 105 I-E molecules/cell, mostly mature heterodimers (see text).
MHC II was visualized with a rabbit polyclonal antibody to I-Ea. The
majority is on the cell surface of blasts, but in intracellular vacuoles in
fresh B cells. (D) Most of the I-E in B blasts consists of mature I-E het-
erodimers. 4-d LPS-induced B blasts from I-E1 BALB/c and I-E2
C57BL/6 mice were lysed and reacted with mAb 14-4-4S to mature I-E
molecules. The immune complexes were bound to beads and then a rab-
bit anti–I-E antibody, which recognizes all forms of I-E, was used to blot
bound and nonbound fractions. Most I-E molecules from B blasts were
bound by 14-4-4S. (E) Macrophages versus immature DCs are the main
site for phagocytosis of B cell fragments in 6-d GM-CSF–stimulated
mouse marrow cultures. Immature MHC II–rich (green) DCs phagocytose
B cell fragments (B220 stain, red), but firmly adherent MHC II–low mac-
rophages contained more numerous intracellular B cell fragments.2169 Inaba et al.
invariant chain–associated or unassembled forms of I-E, but
we believe that 14-4-4S binding reflects the majority of I-E
molecules in the B blasts for the following reasons. First,
using a rabbit antiserum that detects all forms of I-E, we
found that I-E was localized almost exclusively to the sur-
face of 4-d B blasts, whereas in fresh B cells, most I-E was
intracellular in MIICs (Fig. 4 B). In addition, the I-E in 4-d
B blasts was primarily in the mature 14-4-4S detectable
form. The plasma membrane was devoid of detectable in-
variant chain staining, and whole cell lysates adsorbed with
14-4-4S lacked reactivity with rabbit anti–I-E (Fig. 4 C).
We verified that free I-E peptide was not being quickly
degraded upon addition to DCs. If the medium was re-
moved from DCs that had been pulsed with I-Ea peptide
and added to fresh DCs, the Y-Ae signal was 10–30% that
seen with fresh peptide (Fig. 4 D). Therefore, even if every
I-E chain were successfully processed to form an MHC–
peptide complex, B blasts (0.3 nM I-E concentration)
would still be 3,000 times more efficient than free I-Ea
peptide (1 mM) for charging the I-Ab molecules of DCs to
form the Y-Ae epitope. This is an underestimate, since
phagocytosis of B cell fragments by contaminating MHC
II2 macrophages greatly reduced the pool of I-E available
to DCs. In fact, macrophages had 10–20 B cell fragments
on average versus 1–7 fragments per DC (Fig. 4 E).
Efficient Uptake of Donor DCs by Recipient DCs in the T
Cell Areas of Lymph Node. We next asked if DCs could
process antigens from other cells in vivo. We tried injecting
into the footpads of C57BL/6 mice many different cell
types that expressed the I-E peptide and that had been cul-
tured 10 h after being induced to apoptose with UV light
treatment. Only infrequent cells in the T cell area ex-
pressed Y-Ae 2 d later. However, when we injected living,
marrow-derived BALB/c DCs into C57BL/6 mice, large
Y-Ae1 cells were found throughout the T cell area, but not
in the B cell follicles or in the macrophage-rich subcapsular
sinus and medullary regions (Fig. 5 A). These profiles were
shown to be recipient DCs by FACSÒ analysis (Fig. 5 B).
The DCs were first enriched on dense Nycodenz or BSA
columns (20), and then the preparations were double la-
beled, e.g., for the CD11c integrin that is abundant on
DCs. All the Y-Ae was found on CD11c1 B2202 I-Ab1
cells, i.e., recipient DCs. The transfer of I-E peptide from
injected DCs to recipient DCs was efficient, since 2 3 106
DCs contain ,10 3 1011 I-E molecules or 0.05 mg of I-E
protein.
As negative controls, we found that Y-Ae signals did not
develop with H-2k C3H recipients that lacked I-Ab (Fig. 5
B) or with B10.A(4R) allogeneic donor DCs that lacked
the I-E peptide (not shown). Since the donor DCs we used
initially were from BALB/c mice and were incompatible
with C57BL/6 at several major and minor histocompatibil-
ity loci, we injected DCs from C57BL/6 I-E transgenic
mice. The B6.I-E transgenic cells were weak immunogens,
since the cell numbers in the draining lymph nodes did not
increase relative to controls injected with B6 DCs. None-
theless, Y-Ae1 DCs appeared in large numbers in the
draining lymph nodes by day 2 (Fig. 5 C). I-E1 donor DCs
could only be detected in the nodes at day 1, and even then
were outnumbered by recipient I-E2 DCs by 20–50-fold
(not shown). Therefore, I-E peptides can be transferred
from donor to recipient DCs, even in the absence of a ma-
jor immunogenic stimulus.
Discussion
A new approach has become available to study the for-
mation of MHC–peptide complexes by APCs. mAbs have
been isolated that specifically recognize complexes formed
between an MHC class I (25) or class II (18, 26, 27) prod-
uct and a peptide. These antibodies can be used to visualize
antigen presentation, i.e., the expression of MHC–peptide
complexes, at the single cell level rather than the classical
indirect assay of T cell stimulation by bulk populations of
APCs. We have benefited in this paper from the first such
antibody, Y-Ae, which was isolated by Murphy et al. (28)
and shown to recognize a complex of I-Ab presenting a
peptide from another MHC class II product, I-Ea (18, 29).
MHC molecules often present peptides derived from other
MHC products (30), so this kind of complex is not uncom-
mon. Moreover, the Y-Ae complex can be particularly
abundant, especially on DCs within the lymphoid tissues of
F1 mice formed from the cross of C57BL/6 (I-Ab1) and ei-
ther DBA/2 or BALB/c (I-E1; reference 20) mice. The
use of Y-Ae proved valuable for outlining a newly recog-
nized function for DCs, the processing of peptides from
other cells.
This processing of cellular fragments was uncovered in
studies of HLA-A2.11 DCs from human blood (13, 14).
The DCs would present an influenza matrix peptide from
HLA-A2.12 cells that were either infected or transfected
with the influenza matrix gene. MHC class I–peptide com-
plex formation was monitored with functional assays, i.e.,
presentation to CD81 CTLs. The complexes only formed
when apoptotic cells were given to DCs, whereas our cur-
rent studies indicate that processing of cellular fragments
onto MHC class II occurs with both apoptotic and necrotic
cells.
It is not surprising that immature DCs present antigens
from endocytosed particulates, as shown for bacteria (17,
31, 32). However, what is surprising is the efficiency with
which peptides can be extracted from phagocytosed cellular
fragments, in our case from the plasma membrane of B
blasts (Fig. 4). The finding (Fig. 3) that antigen transfer re-
quires acidic compartments implies that the MIICs of DCs
are processing and presentation machines. A protein from
phagocytosed cells can be presented 1–10 thousand times
better than preprocessed peptide, even though the latter is
reasonably stable in culture and is administered to the same
DCs that are fed dying B cells. In ongoing experiments in
which we have monitored MHC–peptide formation by
marrow-derived DCs (and in reports where other APCs
have been studied [26, 27]), 1–10 mM concentrations of
soluble protein and preprocessed peptide must be added to
observe MHC class II–peptide formation. In contrast, when
I-E protein in B blasts is offered to immature DCs, ,1 nM2170 Dendritic Cells Efficiently Process Cellular Fragments
protein leads to strong signals for MHC–peptide formation,
and preprocessed peptide in parallel is .1,000 times less ef-
ficient. This calculation assumes that every I-E protein
molecule is successfully processed to form an MHC–pep-
tide complex. Therefore, we suspect that the success with
which DCs process particulate antigens into MHC–peptide
complexes reflects two things: (a) increased antigen uptake
during adsorptive phagocytosis plus (b) the capacity of DCs
Figure 5. Antigen transfer
from injected DCs to recipient
DCs in vivo in lymph node. (A)
2 3 106 mature, marrow-derived
I-E1 BALB/c DCs were injected
into the footpads of C57BL/6
I-Ab mice. 2 d later, sections of
popliteal nodes were stained for
Y-Ae (blue) and B220 B cell
marker (brown) and photo-
graphed at low and high power
(original magnifications: 350
and  3200). Blue profiles are
scattered throughout the T cell
areas. No blue Y-Ae staining was
seen in several controls: a nonre-
active isotype-matched antibody
to Y-Ae, and donor or recipient
mice that lacked either the I-E
peptide or the I-Ab presenting
molecule (see text). (B) As in A,
but the DCs in the recipient
nodes were enriched for FACSÒ
analyses (reference 20). The cells
were double labeled for Y-Ae or
isotype-matched control mAb
(y-axis) and different cellular
markers (x-axis). The Y-Ae sig-
nals that developed were com-
pared with the expression of “en-
dogenous” Y-Ae in BALB/c 3
B6 F1 mice. Y-Ae1 DCs (arrows)
and B cells (white arrowhead) are
shown. In C57BL/6 mice, most
recipient CD11c1, I-Ab1, B2202
DCs processed I-E and expressed
Y-Ae. (C) As in B, but the DCs
were from B6.I-E transgenic
(right) or B6 mice (left). Process-
ing by host CD11c1 DCs to
form the Y-Ae epitope occurs
when the donor and recipient
DCs differ only in terms of I-E
expression.2171 Inaba et al.
to extract peptides from internalized protein for presenta-
tion on MHC II, as opposed to complete destruction down
to the level of amino acids.
Our results also visualize a possible mechanism whereby
antigens in peripheral tissues can be presented in lymph
nodes to account for cross-priming in the case of trans-
plants and cross-tolerance in the case of self-tissues. Foreign
antigens in allografts and xenografts (5–12) are known to
prime the recipient’s immune system in association with
recipient MHC II products, whereas self-antigens in pan-
creatic islets are known to tolerize the immune system in
association with MHC I (1, 2) and II (3) products on
lymph node APCs. The very act of transplantation causes
DCs to differentiate, to express for example very high lev-
els of MHC II and the CD86 costimulator, and to leave the
transplant (33, 34). In contrast in the steady state, DCs
would not be expected to be stimulated during their traffic
through tissues to afferent lymph and then to the T cell ar-
eas of lymph nodes. Migratory DCs almost certainly die in
the T cell areas, since DCs are not found in thoracic duct
lymph (35–37). We find that migratory DCs can be pro-
cessed, distributing their peptides widely and efficiently to
other DCs to form MHC–peptide complexes. The latter,
detected by the Y-Ae antibody, are unlikely to form in the
periphery, since the turnover of DCs in lymphoid tissues
requires 1–2 wk (38), yet most recipient DCs in lymph
nodes formed Y-Ae in just 1–2 d.
The distinction between cross-priming and cross-toler-
ance may emanate from the maturation state of the incom-
ing DC. If the DC has been activated in the peripheral tis-
sues to express high levels of accessory molecules like
CD86, then some of the incoming DCs should initiate the
immune response. In this case, CD40L and TNF-related
activation–induced cytokine (TRANCE) on the activated
T cell would maintain DC viability (39). In contrast, when
self-antigens from noninflamed tissues are brought to the T
cell areas in the steady state, e.g, if immature DCs would
phagocytose apoptotic cells during the normal turnover of
tissues, T cell stimulation would not occur and the DCs
would die quickly. Then presentation may be initiated by
longer-lived recipient DCs in the lymph node that phago-
cytose the migratory DCs and express proposed regulatory
and tolerogenic functions (40, 41).
We propose that in the steady state, antigens from apop-
totic cells are picked up by peripheral DCs and are pro-
cessed by lymph node DCs to purge the T cell repertoire of
self-reactivity. DCs tolerize developing thymocytes (42–
44). Yet many self-antigens may not have access to the thy-
mus, especially during development of the T cell repertoire
in fetal and neonatal life (45). It may be essential for DCs to
be able to tolerize the repertoire peripherally, since it seems
obligatory that some self-antigens would be presented on
DC MHC products whenever foreign antigens were being
captured and presented. For example, when the I-E pep-
tide we studied here is a self-antigen, the levels of MHC
II–self peptide complexes are very high on DCs (20). DCs
in the periphery are poised to capture antigens and to ma-
ture into strong stimulators of T cell immunity, events that
are induced by inflammatory cytokines and microbial
products (for reviews, see references 46 and 47). Because of
the findings in this paper, i.e., the capacity of DCs to effi-
ciently present peptides from phagocytosed cells and to do
so in vivo during processing of migratory DCs, we suggest
the following pathway to explain the capacity of the im-
mune system to distinguish foreign from self-antigens.
When DCs are presenting foreign, inflammatory, and dan-
gerous antigens (45, 48), the DCs are mature, longer-lived,
and stimulate T cells directly, but reactivity to self is
avoided because self-reactive T cells have previously been
inactivated. This inactivation of self-reactive T cells occurs
via DCs in the thymus, but also in the periphery by the ef-
ficient transfer of self from peripheral to lymph node DCs.
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